ArticleClinical and translational science2025

Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease.

Abigail Samuels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.